Related Experiment Video
Updated: Jun 11, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Automated insulin delivery in type 2 diabetes: a meta-analysis of randomized trials protocol
Luis Gordillo-Rosas1, Cindy Lee Cajachagua-Pucuhuaranga1, Julián Santa Cruz-Venegas1
1Tau Clinical Research Methods Network, Trujillo, Peru.
Background:
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic metabolic disorder, and a substantial proportion of patients eventually require insulin therapy, which is frequently complicated by therapeutic inertia, hypoglycemia and glycemic variability. Automated insulin delivery (AID) systems combine continuous glucose monitoring with algorithm-driven insulin delivery, but their efficacy and safety in adults with T2DM remain uncertain. The objective of this systematic review and meta-analysis is to evaluate the efficacy and safety of AID systems compared with conventional insulin-based strategies in adults with T2DM.
Methods:
The conduct of this review will follow the Cochrane Handbook for Systematic Reviews of Interventions (version 6.5) and reporting will adhere to the PRISMA 2020 and PRISMA-P 2015 statements. Randomized controlled trials (parallel-group and cross-over) evaluating AID systems in adults with T2DM will be identified through a systematic search of MEDLINE (via PubMed), EMBASE, Scopus, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science from inception to 30 November 2025, without language restrictions. The strategy will combine controlled vocabulary, free-text terms, and the Cochrane Highly Sensitive Search Strategy for identifying RCTs; will be developed with input from an expert health-sciences librarian; and will be peer-reviewed using the PRESS 2015 checklist. Two reviewers will independently screen, extract data, and assess risk of bias using the Cochrane Risk of Bias 2 (RoB 2) tool. Pooled estimates will be calculated using random-effects inverse-variance meta-analysis; certainty of evidence will be rated with GRADE.
Discussion:
This review will provide a comprehensive synthesis of randomized evidence on AID systems in T2DM and will inform clinicians, patients, guideline developers, and policymakers about the magnitude of benefit and the safety profile of this technology in routine practice.
Systematic Review Registration:
PROSPERO (CRD420261302666).
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes I: Introduction
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...